Following completion of the dose escalation phase in relapsed/refractory acute leukemia patients with FLT3 mutations, Biomea ...

Gross margin in the first quarter was 53.5%, up 790 basis points from 45.6% in the prior year period Operating expenses in the first quarter were $5.7 million, down 5% as compared to the year-ago ...

Sight Sciences’ management is scheduled to present on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the ...

Nasdaq BioCardia Reports First Quarter 2025 Business Highlights and Financial Results SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and ...

Clearside’s Asia-Pacific collaboration partner, Arctic Vision, announced that its New Drug Application (NDA) for ARCATUS ® (known as XIPERE ® in the U.S.) was formally accepted for review by the ...

Cash position: Tenax Therapeutics reported cash and cash equivalents of $111.4 million as of March 31, 2025. In March 2025, the Company raised approximately $25 million in gross proceeds from a ...

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: ...

Alumis received an upfront license fee of $20.0 million in March 2025 and will receive an additional $20.0 million in near-term co-development payments, with potential for additional milestone ...

The Company is quickly advancing both its Marijuana Breath Test (MBT) with key validation work established in March, and its ...

Medical Advisory Board additions support company’s growing product offerings across women’s health and family building. NEW ...

SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life ...

Cash, cash equivalents and short-term investments were $83.1 million as of March 31, 2025, compared to $125.7 million as of December 31, 2024. Adverum expects its cash, cash equivalents and short-term ...